Investigating a new treatment approach for kidney diseases related to podocyte injury.
Official title: Mechanisms and Selective Modulation of PPARy for the Treatment of Podocytopathies
Funded at State University New York Stony Brook · NIH-11061321 · Data updated 2026-11-12
This study is looking at a new way to help people with kidney diseases by testing a special treatment that could protect kidney cells and reduce protein loss, aiming to make it safer and more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project start | June 15, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $249,639 |
| NIH project number | 5R01DK133440-03 |
| Project ID | NIH-11061321 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with glomerular diseases, particularly those experiencing nephrotic syndrome.
✕Less likely to help
Patients with glomerular diseases that do not involve podocyte injury may not benefit from this research.
What this research studies
This research focuses on glomerular diseases, which often lead to nephrotic syndrome and chronic kidney disease due to podocyte injury. The team aims to explore selective modulation of PPARγ, a receptor that has shown promise in protecting podocytes and reducing proteinuria in previous studies. By moving away from traditional agonists to more selective modulators, the research seeks to improve treatment efficacy while minimizing side effects. Patients may benefit from a targeted therapy that addresses the underlying mechanisms of their kidney disease.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients suffering from nephrotic syndrome and related kidney diseases.
How similar studies have gone: Previous studies have shown success with PPARγ agonists in animal models, but this approach of selective modulation is relatively novel and has not been extensively tested in humans.
Where this research is happening
-
State University New York Stony Brook
Stony Brook, United States Active
Researchers
- Principal investigator: Agrawal, Shipra — State University New York Stony Brook
- Study coordinator: Agrawal, Shipra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.